• Minimize risk and seize opportunities

  • Drug development has never faced more challenges: Increasing costs, growing complexity, longer timelines. Count on Quintiles’ systems, processes and expertise to help you navigate every step.

    • Ensure your trial gets off to the right start with the best possible operational strategy
    • Keep your trial on course with clinical trial management that delivers the efficiencies, rigor, and scale you need
    • Finish strong with a quality NDA submission built on smarter data collection, interpretation and reporting

  • Our Perspectives 

    slider image

    EIU Emerging China

    This Economist Intelligence Unit study, sponsored by Quintiles, looks at China’s growing pharmaceutical market and its implications for the global life sciences sector. Read white paper here

    slider image

    Lifecycle Modeling and Simulation

    Modeling and simulation is poised to transform drug development across the entire lifecycle from discovery to commercialization. Read white paper here

    slider image

    Integration of Molecular Biomarkers into Clinical Development

    Quintiles experts in strategic drug development recommend using biomarkers in anti-cancer therapy research.  Read white paper here

  •  
     
     

    Video Spotlights 

  • Position your clinical trial for success -  from the start

    Quintiles
    Increase your chances of regulatory approval by 11% - with clinical development insights from Quintiles.

    Conducting trials proactively requires immediate decisions about safety, productivity, costs and risks. Read more

    80% of clinical trials don’t meet enrollment deadlines. But you can change those odds with streamlined site selection and patient recruitment. Find out how

    Test-drive your trial to determine the most effective solution before making a huge investment. Learn more

  • Featured News

    Quintiles Rated Industry Leader and Highest in Service Quality in Phase II/III Clinical Research
    Read more

    Quintiles Announces Completion of Initial Public Offering of 27,236,841 Shares of Common Stock
    Read more

    Quintiles Announces Pricing of Initial Public Offering
    Read more

    Our Perspectives

    Harnessing the Power of the Digital Patient White Paper
    Read more

    Tomorrow’s Path to Improved Early-Phase Oncology Drug Development
    Read more

    Strategic Portfolio Management & New Influencers in R&D Decision-Making
    Read more